Canaccord Genuity Group Issues Pessimistic Forecast for Voyager Therapeutics (NASDAQ:VYGR) Stock Price

Voyager Therapeutics (NASDAQ:VYGR - Free Report) had its price objective lowered by Canaccord Genuity Group from $14.00 to $12.00 in a research report released on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts have also recently issued reports about the company. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the stock an "overweight" rating in a research note on Wednesday, March 12th. Cantor Fitzgerald reissued an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Citigroup initiated coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a "buy" rating and a $12.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday. Finally, StockNews.com lowered Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, December 13th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $14.86.

Remove Ads

Voyager Therapeutics Stock Down 0.3 %

NASDAQ VYGR traded down $0.01 on Thursday, reaching $3.89. The company had a trading volume of 254,571 shares, compared to its average volume of 477,172. Voyager Therapeutics has a 52 week low of $3.56 and a 52 week high of $10.66. The stock has a market cap of $212.50 million, a price-to-earnings ratio of 5.48 and a beta of 0.99. The stock's 50 day moving average is $4.79 and its 200-day moving average is $5.80.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $4.39 million for the quarter, compared to analyst estimates of $16.58 million. During the same period in the previous year, the business posted $1.25 EPS. As a group, analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current year.

Insiders Place Their Bets

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares of the company's stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 10,778 shares of company stock worth $58,548. Company insiders own 4.53% of the company's stock.

Institutional Trading of Voyager Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in shares of Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company's stock worth $6,316,000 after buying an additional 6,740 shares in the last quarter. FMR LLC lifted its holdings in Voyager Therapeutics by 26.9% during the third quarter. FMR LLC now owns 92,498 shares of the company's stock worth $541,000 after acquiring an additional 19,622 shares during the period. Barclays PLC grew its stake in Voyager Therapeutics by 55.8% in the 3rd quarter. Barclays PLC now owns 104,462 shares of the company's stock valued at $612,000 after purchasing an additional 37,398 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of Voyager Therapeutics by 23.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock valued at $223,000 after purchasing an additional 7,573 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Voyager Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock worth $405,000 after purchasing an additional 2,354 shares during the period. 48.03% of the stock is owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.